ERBB2 and breast cancer: For instance, in the I-SPY2 trial, among ER-positive/HER2-negative BC classified as high-risk on MammaPrint, a basal-like intrinsic subtype was associated with a 67% pCR with pembrolizumab added to NACT (66).